Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Abion Inc. currently manages a portfolio in the Biotechnology & Pharmaceuticals technology area that includes 3 pending office actions. These matters are distributed across 3 distinct examiners and 3 distinct art units, which indicates that the company's biotechnology filings are being reviewed by multiple USPTO professionals. This distribution means that the prosecution strategy must be adaptable to the different styles and requirements of 3 distinct art units.
KASSA, TIGABU is identified as the busiest examiner for the portfolio, although this individual is responsible for 1 busiest examiner pending action. This means that the 3 pending office actions are split, with 3 distinct examiners each handling a portion of the workload. Navigating 3 distinct art units requires the company to address the specialized biotechnology standards of each group, as no 1 examiner or unit dominates the 3 pending office actions currently active.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| §102 only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
| ANGELL, JON E | 1 | 71.0% | +21.1% |
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +57.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18267459 | METHOD FOR PREPARING PHARMACEUTICAL FORMULATION OF TABLET CONTAINING TRIZOLOPYRAZINE DERIVATIVE AS AN ACTIVE INGREDIENT | KASSA, TIGABU | — |
| 18013811 | CORONAVIRUS-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDES, AND COMPOSITION COMPRISING SAME FOR PREVENTING AND TREATING CORONAVIRUS DISEASE-19 | ANGELL, JON E | — |
| 17627840 | METHOD FOR PURIFYING DIGLYCOSYLATED INTERFERON-BETA PROTEIN | ESPINOSA, CLAUDIA EDILMA | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| 1637 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18267459 | METHOD FOR PREPARING PHARMACEUTICAL FORMULATION OF TABLET CONTAINING TRIZOLOPYRAZINE DERIVATIVE AS AN ACTIVE INGREDIENT | KASSA, TIGABU | 1619 | §103 | Final Rejection | — | Pending | Jun 15, 2023 |
| 18013811 | CORONAVIRUS-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDES, AND COMPOSITION COMPRISING SAME FOR PREVENTING AND TREATING CORONAVIRUS DISEASE-19 | ANGELL, JON E | 1637 | §102 | Final Rejection | — | Pending | Dec 29, 2022 |
| 17627840 | METHOD FOR PURIFYING DIGLYCOSYLATED INTERFERON-BETA PROTEIN | ESPINOSA, CLAUDIA EDILMA | 1654 | §103 | Non-Final OA | — | Pending | Jan 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial